<DOC>
	<DOCNO>NCT01097278</DOCNO>
	<brief_summary>RATIONALE : Cholecalciferol may prevent breast cancer premenopausal woman . PURPOSE : This randomized phase II trial study well cholecalciferol work prevent breast cancer premenopausal woman .</brief_summary>
	<brief_title>S0812 High Dose Cholecalciferol Premenopausal Women High-Risk Breast Cancer</brief_title>
	<detailed_description>OBJECTIVES : - To assess whether mammographic density reduce premenopausal woman high risk breast cancer take high-dose vitamin D3 ( oral cholecalciferol 20,000 IU weekly ) v placebo 1 year . - To assess whether proliferation measure Ki-67 stain breast epithelial cell reduce woman receive treatment . - To explore difference expression biomarkers ( include cleave caspase-3 [ apoptosis marker ] , ER , vitamin D receptor [ VDR ] , 1α-hydroxylase ) breast tissue obtain woman . - To assess whether parathyroid hormone , IGF-1 , IGFBP-3 , 25 ( OH ) D , 1,25 ( OH ) D serum level alter woman baseline 6 12 month . - To explore whether change mammographic density correlate polymorphisms VDR gene . - To assess source vitamin D ( sunlight exposure , diet ) woman use validated questionnaire administer baseline 12 24 month . - To collect bank serum , plasma , breast tissue woman 1-year intervention vitamin D future biomarker analysis . - To assess toxicity high-dose cholecalciferol compare placebo set . OUTLINE : This multicenter study . Participants stratify accord baseline serum 25 ( OH ) D level ( &lt; 20 ng/mL vs 20-32 ng/mL &lt; 50 nmol/L vs 50-80 nmol/L ) , baseline mammographic density ( 11-50 % v &gt; 50 % ) , designate biopsy site ( yes v ) . Participants randomize 1 2 treatment arm . - Arm I : Participants receive oral cholecalciferol weekly oral vitamin D daily . Treatment repeat 12 month absence evidence cancer unacceptable toxicity . - Arm II : Participants receive oral placebo weekly oral vitamin D daily . Treatment repeat 12 month absence evidence cancer unacceptable toxicity . Blood sample collect baseline periodically thereafter biomarkers 25 ( OH ) D level . Participants undergo mammogram baseline 12 month . Participants may also undergo random core-needle breast biopsy baseline 12 month . Participants complete questionnaire baseline 12 24 month . After completion study therapy , participant follow 1 12 month .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Vitamins</mesh_term>
	<mesh_term>Vitamin D</mesh_term>
	<mesh_term>Cholecalciferol</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : At elevate risk breast cancer least one follow criterion : Diagnosis ADH , ALH , lobular carcinoma situ ( LCIS ) resect ductal carcinoma situ ( DCIS ) small invasive breast cancer ( pTmi pT1a N0 ) pior RT , tamoxifen , systemic breast cancer treatment within 28 day prior registration OR diagnosis resect Stage I ( T1bc N0N1mi ) Stage II breast cancer participant diseasefree least 5 year complete adjuvant treatment OR A known* deleterious mutation BRCA1 , BRCA2 , PTEN , TP53 NOTE : *The participant must document carrier meet criterion . If know mutation hereditary breast cancer susceptibility gene participant 's family member , participant must undergo genetic test per NCCN clinical guideline eligible per criterion . Modified Gail Model/CARE model** risk 5 year ≥ 1.67 % lifetime risk ≥ 20 % Claus , BRCAPro , TyrerCuzick IBIS model OR Mammographic density ≥ 50 % ( heterogenously dense ) NOTE : **Risk model use know previous diagnosis resect DCIS LCIS know deleterious mutation BRCA1 , BRCA2 , PTEN , TP53 . At least one breast available image biopsy ( previously irradiate breast [ i.e. , resect DCIS ] evaluable breast image biopsy ) Baseline mammogram ( perform within 10 day start last menstrual period digital mammography machine ) show either normal benign finding Baseline mammographic density &gt; 10 % base upon classification system ( 2 = 1150 % , `` scatter fibroglandular density '' ; 3 = 5175 % , `` heterogeneously dense '' ; 4 = &gt; 75 , `` extremely dense '' . Women baseline mammographic density ≤ 10 % ( 1 = ≤ 10 % breast almost entirely fat ) eligible . PATIENT CHARACTERISTICS : Premenopausal , define ≥ 1 follow criterion : Less 6 month since last menstrual period , prior bilateral oophorectomy , use hormonereplacement therapy Has undergone prior hysterectomy prior bilateral oophorectomy AND folliclestimulating hormone value measure within past 28 day consistent normal value premenopausal state Zubrod performance status 01 Serum creatinine ≤ upper limit normal ( ULN ) Serum calcium correct calcium ≤ ULN Spot urine calcium : creatinine ratio &lt; 0.37 mg/dL INR ≤ 1.5 time ULN+ PT PTT ≤ ULN* Baseline serum 25 ( OH ) D level ≤ 32 ng/mL ( 80 nmol/L ) Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No prior malignancy except follow : Adequately treat basal cell squamous cell skin cancer In situ cervical cancer Adequately treat stage I II ( include resect Stage I , T1bc N0N1mi Stage II breast cancer ) participant currently complete remission Any cancer ( include contralateral breast ) participant diseasefree ≥ 5 year No history kidney stone No medical condition require calcium vitamin D supplementation ( i.e. , osteoporosis ) No know hypersensitivity vitamin D No known allergy soy NOTE : +For patient undergo breast biopsy . PRIOR CONCURRENT THERAPY : Prior breast reduction surgery allow No bilateral breast implant More 1 month since prior surgery radiotherapy breast resect DCIS At least 28 day since prior tamoxifen Prior anticoagulant therapy allow provide discontinue ≥ 7 day breast biopsy No concurrent calcium additional vitamin D supplement Concurrent multivitamin allow provide dose vitamin D multivitamin exceed 400 IU daily No concurrent participation clinical trial treatment prevention cancer unless participant long receive intervention followup phase ( participant must join trial participate study )</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>breast cancer</keyword>
	<keyword>ductal breast carcinoma situ</keyword>
	<keyword>lobular breast carcinoma situ</keyword>
	<keyword>BRCA1 mutation carrier</keyword>
	<keyword>BRCA2 mutation carrier</keyword>
</DOC>